

Supporting Information for

Design, synthesis and induced fit docking study of D-glucose-conjugated thioureas containing pyrimidine ring and their inhibition activity against α -amylase, α -glucosidase (ddP-4, PTP1B) in treatment for Type II diabetes mellitus

Vu Ngoc Toan,^{a,b} Do Son Hai,^{a,c} Hoang Thi Kim Van,^{a,d} Nguyen Minh Tri,^{a,b} Duong Ngoc Toan,^{a,e} Nguyen Thi Thanh Mai,^{a,f} Nguyen Dinh Thanh*^a

^a Faculty of Chemistry, University of Science (Vietnam National University, Hanoi), 19 Le Thanh Tong, Hoan Kiem, Ha Noi, Viet Nam

^b Institute of New Technology, Academy of Military Science and Technology, Ministry of Defence, 17 Hoang Sam, Cau Giay, Ha Noi, Viet Nam


^c Institute of Science and Technology, Ministry of Public Security of Vietnam, 47 Pham Van Dong, Cau Giay, Ha Noi, Viet Nam

^d Faculty of Chemical Technology, Viet Tri University of Industry, Tien Kien, Lam Thao, Phu Tho, Viet Nam

^e Faculty of Chemistry, Thai Nguyen University of Education, Address: 20 Luong Ngoc Quyen, Thai Nguyen, Viet Nam

^f Faculty of Chemical Technology, Ha Noi University of Industry, 298 Cau Dien Road, North Tu Liem, Ha Noi, Viet Nam

Reaction Scheme



1. General procedure for synthesis of α,β -unsaturated ketones (chalcones) (3a-l)

Appropriate (un)substituted benzaldehydes (**1a-l**, 0.02 mol) was dissolved into 96% ethanol (5 mL), then 4-bromoacetophenone (**2**, 0.02 mol, 3.98 g) was added with stirring. Next, potassium hydroxide solution (that was prepared from 0.84 g KOH in 4 ml of water) was slowly dropped into the stirring reaction mixture while reaction temperature was always kept at about 15-20°C. After that, the reaction mixture was stirred further for 4-5 h at r.t. (controlled by TLC, ethyl acetate/*n*-hexane solvent, ratio of 2: 1 in volume). The solid product was collected by filtration and washed the product thoroughly with cold to neutral reaction. Raw product of yellow or light-yellow colour was obtained. After recrystallization from ethanol or ethanol-toluene mixture (ration of 1:1 in volume) to afford α,β -unsaturated ketone **3a-l** as needle-shaped crystals.¹⁻⁴

1.1. (E)-1-(4-Bromophenyl)-3-phenylprop-2-en-1-one (3a)

From **1** and **2a** (0.02 mol, 3.70 g). Yield: 4.59 g (80%). M.p.: 111–112°C. Ref.:⁵ No m.p. data, ref. :⁶ 96–98°C.

1.2. (E)-1-(4-Bromophenyl)-3-(4-fluorophenyl)prop-2-en-1-one (3b)

From **1** and **2b** (0.02 mol, 2.48 g). Yield: 4.76 g (78%). M.p.: 99–100°C. Ref.:⁷ 89–93°C.

1.3. (E)-1-(4-Bromophenyl)-3-(4-chlorophenyl)prop-2-en-1-one (3c)

From **1** and **2c** (0.02 mol, 2.81 g). Yield: 5.10 g (78%). M.p.: 161–162°C. Ref.:⁸ No m.p. data.

1.4. (E)-1-(4-Bromophenyl)-3-(3-chlorophenyl)prop-2-en-1-one (3d)

From **1** and **2d** (0.02 mol, 2.81 g). Yield: 4.95 g (77%). M.p.: 90–91°C. Ref.:⁸ No m.p. data.

1.5. (E)-1-(4-Bromophenyl)-3-(2-chlorophenyl)prop-2-en-1-one (3e)

From **1** and **2e** (0.02 mol, 2.81 g). Yield: 4.10 g (62%). M.p.: 69–70°C. Ref.:⁹ No m.p. data.

1.6. (E)-1,3-bis(4-bromophenyl)prop-2-en-1-one (3f)

From **1** and **2f** (0.02 mol, 3.70 g). Yield: 4.30 g (75%). M.p.: 166–167°C. Ref.:¹⁰ No m.p. data.

1.7. (E)-1-(4-Bromophenyl)-3-(4-methylphenyl)prop-2-en-1-one (3g)

From **1** and **2g** (0.02 mol, 2.40 g). Yield: 4.64 g (77%). M.p.: 81–82°C. Ref.:¹¹ No m.p. data.

1.8. (E)-1-(4-Bromophenyl)-3-(4-isopropylphenyl)prop-2-en-1-one (3h)

From **1** and **2g** (0.02 mol, 2.96 g). Yield: 5.26 g (80%). M.p.: 86–87°C. Ref.:⁸ No m.p. data..

1.9. (E)-1-(4-Bromophenyl)-3-(4-methoxyphenyl)prop-2-en-1-one (3i)

From **1** and **2i** (0.02 mol, 2.72 g). Yield: 4.44 g (70%). M.p.: 120–121°C. Ref.:¹² No m.p. data.

1.10. (E)-1-(4-Bromophenyl)-3-(3-methoxyphenyl)prop-2-en-1-one (3j)

From **1** and **2j** (0.02 mol, 2.72 g). Yield: 3.93 g (62%). M.p.: 69–70°C. Ref.:¹³ No m.p. data.

1.11. (E)-1-(4-Bromophenyl)-3-(2-methoxyphenyl)prop-2-en-1-one (3k)

From **1** and **2k** (0.02 mol, 2.72 g). Yield: 4.50 g (71%). M.p.: 89–90°C. Ref.:¹³ No m.p. data.

1.12. (E)-1-(4-Bromophenyl)-3-(4-(dimethylamino)phenyl)prop-2-en-1-one (3l)

From **1** and **2l** (0.02 mol, 2.98 g). Yield: 5.08 g (77%). M.p.: 115–116°C. Ref.:¹⁴ No m.p. data.

2. General procedure for synthesis of 2-(4-bromophenyl)-6-aryl-2-aminopyrimidines (4a-l)

These 2-aminopyrimidines were obtained from corresponding chalcone by its reaction with guanidine hydrochloride in 96% ethanol in the presence of NaOH as base (Scheme 1) using three different procedures were studied, including **Procedure A** (using conventional heating method, with solid NaOH in 96% EtOH under reflux conditions for 12–14 h), **Procedure B** (using microwave-assisted heating method under reflux conditions), with solid NaOH in 96% EtOH for 7–9 min), and **Procedure C** (using microwave-assisted heating solvent-free method with solid NaOH for 15–18 min, see Table 1S in SI). The yields achieved for each procedure were 61–82%, 74–81%, and 68–88%, respectively. From the data in Table 1S, we see that Proc. B could be considered the

optimal procedure for synthesizing substituted 2-aminopyrimidines **4a-l**.

Table 1S. Synthesis of substituted 2-amino-4-(4-bromophenyl)-6-arylpyrimidines (**4a-l**)

Com pd.	R	Reaction times ^a			Yields (%) ^b			M.p. (°C)
		Proc. A (h)	Proc. B (min)	Proc. C (min)	Proc. A	Proc. B	Proc. C	
4a	H	12	8	15	70	74	86	171–172
4b	4-F	13	9	17	76	79	76	198–199
4c	4-Cl	13	9	17	82	82	76	219–220
4d	3-Cl	14	9	18	79	81	78	184–185
4e	2-Cl	14	9	15	61	77	56	170–171
4f	4-Br	12	8	16	78	78	68	225–226
4g	4-Me	10	7	15	75	78	77	152–153
4h	4- ⁱ Pr	10	7	15	80	81	76	155–156
4i	4-OMe	10	7	15	80	80	77	171–172
4j	3-OMe	10	7	15	77	80	80	182–183
4k	2-OMe	12	8	16	76	77	80	150–151
4l	4-NMe ₂	10	7	15	80	80	82	185–186

Notes: **Procedure A** (using conventional heating method): solid NaOH (7.5 mmol), 96% EtOH (20 mL), under reflux for 10–14 h; **Procedure B** (using microwave-assisted heating method): solid NaOH (7.5 mmol), 96% EtOH (5 mL), under reflux for 7–9 min; **Procedure C** (using microwave-assisted heating method under solvent-free conditions): solid NaOH (7.5 mmol), 15–18 min; ^b Isolated yields.

Procedure A: Using conventional heating method under reflux

Appropriate chalcone (**3a-l**, 5 mmol) was dissolved in 96% ethanol (20 mL) then guanidine hydrochloride (7.5 mmol, 0.7 g) and solid NaOH (22.5 mol, 0.9 g) were added to this solution. The reaction mixture was heated under reflux for 10–14 h. The solvent was removed under reduced pressure and water was added. The separated product as a solid was filtered washed with water to a neutral reaction. Recrystallization from ethanol/toluene mixture (1: 1 by volume) to afford the titled 2-(4-bromophenyl)-6-aryl-2-aminepyrrimidines (**-a-l**).¹⁵

Procedure B: Using microwave-assisted heating method under reflux conditions

A reaction mixture of appropriate substituted benzylideneacetophenones (**3a-l**, 5 mmol), guanidine hydrochloride (7.5 mmol) and sodium hydroxide (22.5 mmol) were mixed carefully in 96% ethanol

(5 mL). Then, the reaction mixture was heated under microwave-assisted for 7–9 min, the reaction mixture had become dark-yellow. Upon completion, monitored by TLC, the reaction mixture was cooled to room temperature and then triturated with water and the formed precipitate was filtered by suction and washed with water until neutral to afford the titled compounds **4a-l**, recrystallized from 1: 1 EtOH-toluene to give ivory-white crystals.

Procedure C: Using microwave-assisted heating method under solvent-free conditions

A reaction mixture of appropriate substituted benzylideneacetophenones (**3a-l**, 5 mmol), guanidine hydrochloride (7.5 mmol) and sodium hydroxide (22.5 mmol) were mixed carefully with a little water so that the gelatinous mass is received. Then, the reaction mixture was heated under microwave-assisted conditions for 15–18 min, the reaction mixture had become dark-yellow. Upon completion, monitored by TLC, the reaction mixture was cooled to room temperature and then triturated with water and the formed precipitate was filtered by suction and washed with water until neutral to afford the titled compounds **4a-l**, recrystallized from 1: 1 EtOH-toluene to give ivory-white crystals.

2.1. 4-(4-Bromophenyl)-6-phenylpyrimidin-2-amine (4a)

From (*E*)-1-(4-bromophenyl)-3-phenylprop-2-en-1-one (**3a**, 5 mmol, 1.19 g). M.p.: 171–172°C. Yield: 1.14 g (70%, Proc. A), 1.21 g (74%, Proc. B), 1.40 g (86%, Proc. C), 1.12 g (69%, QTA2-3). ¹³C NMR (500 MHz, DMSO-*d*₆), δ (ppm): 8.22–8.21 (m, 2H, H-3' & H-5' phenyl), 8.18 (d, *J* = 8.5 Hz, 2H, H-3'' & H-5'' phenyl), 7.72 (d, *J* = 8.5 Hz, 2H, H-2'' & H-4'' phenyl), 7.71 (s, 1H, H-5 pyrimidine), 7.53–7.51 (m, 3H, H-2', H-4' & H-6' phenyl), 6.76 (s, 2H, 2-NH₂ amine); ¹³C NMR (125 MHz, DMSO-*d*₆), δ (ppm): 162.10, 158.56, 158.54, 136.34, 132.10, 131.46, 129.51, 128.74, 127.79, 127.50, 121.76, 108.35.

2.2. 4-(4-Bromophenyl)-6-(4-fluorophenyl)pyrimidin-2-amine (4b)

From (*E*)-1-(4-bromophenyl)-3-(4-fluorophenyl)prop-2-en-1-one (**3b**, 5 mmol, 1.53 g). M.p.: 198–199°C. Yield: 1.37 g (76%, Proc. A), 1.42 g (79%, Proc. B), 1.37 g (76%, Proc. C). NMR (500 MHz, DMSO-*d*₆), δ (ppm): 8.29 (dd, *J* = 9.0 Hz, *J*_{HF} = 5.5, 2H, H-2'' phenyl & H-6'' phenyl), 8.20 (d, *J* = 8.5 Hz, 2H, H-2' & H-6' phenyl), 7.74 (s, 1H, H-5 pyrimidine), 7.72 (t, *J* = 8.5 Hz, 2H, H-3' & H-5' phenyl), 7.35 (t, *J* = 8.5 Hz, 2H, H-3'' & H-5'' phenyl), 6.79 (s, 2H, 2-NH₂ amine); ¹³C NMR (125 MHz, DMSO-*d*₆), δ (ppm): 164.65, 162.63, 162.13, 159.11, 158.56, 131.95, 131.50, 129.93, 129.90, 128.13, 128.07, 127.79, 121.84, 115.72, 115.56, 108.38.

2.3. 4-(4-Bromophenyl)-6-(4-chlorophenyl)pyrimidin-2-amine (4c)

From (*E*)-1-(4-bromophenyl)-3-(4-chlorophenyl)prop-2-en-1-one (**3c**, 5 mmol, 1.16 g). M.p.: 219–222°C. Yield: 1.48 g (82%, Proc. A), 1.48 g (82%, Proc. B), 1.37 g (76%, Proc. C). ¹H NMR (500 MHz, DMSO-*d*₆), δ (ppm): 8.25 (d, *J* = 8.5 Hz, 2H, H-2'' & H-6'' phenyl), 8.18 (d, *J* = 8.5 Hz, 2H, H-2' & H-6' phenyl), 7.72 (d, *J* = 8.5 Hz, 2H, H-3' & H-5' phenyl), 7.59 (s, 1H, H-5 pyrimidine), 7.58 (d, *J* = 8.5 Hz, 2H, H-3'' & H-5'' phenyl), 6.82 (s, 2H, 2-NH₂ amine); ¹³C NMR (125 MHz, DMSO-*d*₆), δ (ppm): 162.13, 158.61, 158.06, 135.90, 131.91, 131.52, 131.43, 128.79, 128.68, 127.80, 121.90, 108.38.

2.4. 4-(4-Bromophenyl)-6-(3-chlorophenyl)pyrimidin-2-amine (4d)

From (*E*)-1-(4-bromophenyl)-3-(3-chlorophenyl)prop-2-en-1-one (**3d**, *J* = 5 mmol, 1.16 g). M.p.: 184–185°C. Yield: 1.42 g (79%, Proc. A), 1.46 g (81%, Proc. B), 1.40 g (78%, Proc. C). NMR (500 MHz, DMSO-*d*₆), δ (ppm): 8.31–8.30 (m, 1H, H-2'' phenyl), 8.22–8.19 (m, 1H, H-6'' phenyl), 8.21 (d, *J* = 9.0 Hz, 2H, H-2' & H-6' phenyl), 7.81 (s, 1H, H-5 pyrimidine), 7.73 (d, *J* = 9.0 Hz, 2H, H-3' & H-5' phenyl), 7.59–7.54 (m, 2H, H-4'' & H-5'' phenyl), 6.86 (s, 2H, 2-NH₂ amine); ¹³C NMR (125 MHz, DMSO-*d*₆), δ (ppm): 162.19, 158.46, 158.07, 134.82, 132.90, 131.91, 131.52, 129.66, 128.98, 127.80, 126.79, 125.27, 121.90, 108.89.

2.5. 4-(4-Bromophenyl)-6-(2-chlorophenyl)pyrimidin-2-amine (4e)

From (*E*)-1-(4-bromophenyl)-3-(3-chlorophenyl)prop-2-en-1-one (**3e**, 5 mmol, 1.16 g). M.p.: 170–171°C. Yield: 1.10 g (61%, Proc. A), 1.39 g (77%, Proc. B), 1.00 g (56%, Proc. C). NMR (500 MHz, DMSO-*d*₆), δ (ppm): 8.07 (d, *J* = 8.5 Hz, 2H, H-2' & H-6' phenyl), 7.71 (d, *J* = 8.5 Hz, 2H, H-3' & H-5' phenyl), 7.61–7.57 (m, 2H, H-3'' & H-6'' phenyl), 7.49–7.46 (m, 2H, H-4'' & H-5'' phenyl), 7.34 (s, 1H, H-5 pyrimidine), 6.89 (s, 2H, 2-NH₂ amine); ¹³C NMR (125 MHz, DMSO-*d*₆), δ (ppm): 162.68, 158.74, 158.65, 133.38, 133.05, 131.78, 131.52, 130.87, 128.93, 128.84, 127.80, 126.81, 121.90, 108.80.

2.6. 4,6-bis(4-Bromophenyl)pyrimidin-2-amine (4f)

From (*E*)-1-bis(4-bromophenyl)prop-2-en-1-one (**3f**, 5 mmol, 1.83 g). M.p.: 225–226°C. Yield: 1.58 g (78%, Proc. A), 1.58 g (78%, Proc. B), 1.38 g (68%, Proc. C). NMR (500 MHz, DMSO-*d*₆), δ (ppm): 8.18 (d, *J* = 8.5 Hz, 4H, H-2', H-6' & H-2'', H-6'' phenyl), 7.76 (s, 1H, H-5 pyrimidine), 7.73 (d, *J* = 8.5 Hz, 4H, H-3', H-5' & H-3'', H-5'' phenyl), 6.83 (s, 2H, 2-NH₂ amine); ¹³C NMR (125 MHz, DMSO-*d*₆), δ (ppm): 162.13, 158.95, 132.01, 131.43, 128.00, 121.78, 108.38.

2.7. 4-(4-Bromophenyl)-6-(4-methylphenyl)pyrimidin-2-amine (4g)

From (*E*)-1-(4-bromophenyl)-3-(4-methylphenyl)prop-2-en-1-one (**3g**, 5 mmol, 1.51 g). M.p.: 152–153°C. Yield: (80%, Proc. A), (80%, Proc. B), (82%, Proc. C). NMR (500 MHz, DMSO-*d*₆), δ (ppm): 8.18 (d, $J = 8.5$ Hz, 2H, H-2' & H-6' phenyl), 8.13 (d, $J = 8.0$, 2H, H-2'' & H-6'' phenyl), 7.71 (d, $J = 8.5$ Hz, 2H, H-3' & H-5' phenyl), 7.70 (s, 1H, H-5 pyrimidine), 7.32 (d, $J = 8.0$ Hz, 2H, H-3'' & H-5'' phenyl), 6.74 (s, 2H, 2-NH₂ amine), 2.37 (s, 2H, 4''-CH₃ phenyl); ¹³C NMR (125 MHz, DMSO-*d*₆), δ (ppm): 162.13, 158.56, 158.45, 140.37, 131.95, 131.55, 131.50, 128.96, 128.06, 127.79, 121.59, 108.31, 21.23.

2.8. 4-(4-Bromophenyl)-6-(4-isopropylphenyl)pyrimidin-2-amine (4h)

From (*E*)-1-(4-bromophenyl)-3-(4-methylphenyl)prop-2-en-1-one (**3h**, 5 mmol, 1.64 g). M.p.: 155–156°C. Yield: 1.47 g (80%, Proc. A), 1.49 g (81%, Proc. B), 1.40 g (76%, Proc. C). NMR (500 MHz, DMSO-*d*₆), δ (ppm): 8.17 (d, $J = 8.5$ Hz, 2H, H-2' & H-6' phenyl), 8.14 (d, $J = 8.25$ Hz, 2H, H-2'' & H-6'' phenyl), 7.72 (d, $J = 8.5$ Hz, 2H, H-3' & H-5' phenyl), 7.69 (s, 1H, H-5 pyrimidine), 7.38 (d, $J = 8.25$ Hz, 2H, H-3'' & H-5'' phenyl), 6.74 (s, 2H, 2-NH₂ amine), 2.96 [septet, $J = 7.75$ Hz, 1H, 4''-CH(CH₃)₂ phenyl], 1.24 [d, $J = 7.75$ Hz, 6H, 4''-CH(CH₃)₂ phenyl]; ¹³C NMR (125 MHz, DMSO-*d*₆), δ (ppm): 161.79, 157.31, 157.29, 147.18, 132.32, 132.25, 131.46, 128.46, 127.97, 125.61, 121.73, 108.47, 33.75, 23.93.

2.9. 4-(4-Bromophenyl)-6-(4-methoxyphenyl)pyrimidin-2-amine (4i)

From (*E*)-1-(4-bromophenyl)-3-(4-methoxyphenyl)prop-2-en-1-one (**3i**, 5 mmol, 1.59 g). M.p.: 171–172°C. Yield: 1.42 g (80%, Proc. A), 1.42 g (80%, Proc. B), 1.37 g (77%, Proc. C). NMR (500 MHz, DMSO-*d*₆), δ (ppm): 8.20 (d, $J = 8.5$ Hz, 2H, H-2'' & H-6'' phenyl), 8.17 (d, $J = 8.5$ Hz, 2H, H-2' & H-6' phenyl), 7.71 (d, $J = 8.5$ Hz, 2H, H-3'' & H-5'' phenyl), 7.68 (s, 1H, H-5 pyrimidine), 7.06 (d, $J = 8.5$ Hz, 2H, H-3' & H-5' phenyl), 6.69 (s, 2H, 2-NH₂ amine), 3.84 (s, 3H, 4'-OCH₃ phenyl); ¹³C NMR (125 MHz, DMSO-*d*₆), δ (ppm): 162.13, 159.13, 158.44, 158.06, 132.00, 131.46, 128.62, 128.19, 127.80, 121.90, 114.00, 108.80, 55.33.

2.10. 4-(4-Bromophenyl)-6-(3-methoxyphenyl)pyrimidin-2-amine (4j)

From (*E*)-1-(4-bromophenyl)-3-(3-methoxyphenyl)prop-2-en-1-one (**3j**, 5 mmol, 1.59 g). M.p.: 182–183°C. Yield: 1.37 g (77%, Proc. A), 1.42 g (80%, Proc. B), 1.42 g (80%, Proc. C). NMR (500 MHz, DMSO-*d*₆), δ (ppm): 8.19 (d, $J = 8.5$ Hz, 2H, H-2' & H-6' phenyl), 7.80 (d, $J = 7.5$ Hz, 1H, H-6'' phenyl), 7.76 (d, $J = 2.5$ Hz, 1H, H-2'' phenyl), 7.73 (d, $J = 8.5$ Hz, 2H, H-3' & H-5' phenyl), 7.72 (s, 1H, H-5 pyrimidine), 7.43 (t, $J = 7.5$ Hz, 1H, H-5'' phenyl), 7.09 (dd, $J = 2.5, 8.0$ Hz, 1H, H-4'' phenyl), 6.78 (s, 2H, 2-NH₂ amine), 3.85 (s, 3H, 3''-OCH₃ phenyl); ¹³C NMR (125 MHz,

DMSO-*d*₆), δ (ppm): 162.19, 160.00, 158.69, 158.46, 132.30, 132.00, 131.46, 129.53, 127.80, 121.95, 121.90, 114.43, 111.09, 108.95, 55.31.

2.11. 4-(4-Bromophenyl)-6-(2-methoxyphenyl)pyrimidin-2-amine (4k)

From (*E*)-1-(4-bromophenyl)-3-(2-methoxyphenyl)prop-2-en-1-one (**3k**, 5 mmol, 1.59 g). M.p.: 150–151°C. Yield: 1.35 g (76 %, Proc. A), 1.37 g (77%, Proc. B), 1.42 g (80%, Proc. C). NMR (500 MHz, DMSO-*d*₆), δ (ppm): 7.86 (m, 2H, H-2' & H-6' phenyl), 7.77 (s, 1H, H-5 pyrimidine), 7.68 (dd, $J = 1.5, 7.5$ Hz, 1H, H-6'' phenyl), 7.58 (m, 2H, H-3' & H-5' phenyl), 7.38 (td, $J = 1.5, 7.5$ Hz, 1H, H-4'' phenyl), 7.14 (td, $J = 1.5, 7.5$ Hz, 1H, H-5'' phenyl), 7.10 (d, $J = 7.5$ Hz, 1H, H_a in NH₂ amine), 6.90 (dd, $J = 1.5, 7.5$ Hz, 1H, H-3'' phenyl), 6.08 (d, $J = 7.5$ Hz, 1H, H_a in NH₂ amine), 3.84 (s, 4'- OCH₃ phenyl); ¹³C NMR (125 MHz, DMSO-*d*₆), δ (ppm): 162.31, 159.43, 158.14, 156.51, 131.78, 131.46, 130.98, 128.81, 127.80, 124.56, 121.90, 120.79, 113.86, 108.60, 55.75.

2.12. 4-(4-Bromophenyl)-6-(4-(dimethylamino)phenyl)pyrimidin-2-amine (4l)

From (*E*)-1-(4-bromophenyl)-3-(4-(dimethylamino)phenyl)prop-2-en-1-one (**3l**, 5 mmol, 1.65 g). M.p.: 185–186°C. Yield: 1.48 g (80%, Proc. A), 1.48 g (80%, Proc. B), 1.52 g (82%, Proc. C). NMR (500 MHz, DMSO-*d*₆), δ (ppm): 8.15 (d, $J = 8.5$ Hz, 2H, H-2' & H-6' phenyl), 8.10 (d, $J = 8.75$ Hz, 2H, H-2'' & H-6'' phenyl), 7.70 (d, $J = 8.5$ Hz, 2H, H-3' & H-5' phenyl), 7.59 (s, 1H, H-5 pyrimidine), 6.78 (d, $J = 8.75$ Hz, 2H, H-3'' & H-5'' phenyl), 6.55 (s, 2H, 2-NH₂ amine), 3.00 [s, 6H, 4''-N(CH₃)₂ phenyl]; ¹³C NMR (125 MHz, DMSO-*d*₆), δ (ppm): 161.79, 157.86, 157.31, 151.48, 132.25, 131.46, 128.47, 128.22, 127.97, 121.73, 112.08, 108.47, 40.26.

3. General procedure for synthesis of 4,6-diarylpyrimidine thioureas (8a-l)

Two synthesis procedures were applied (*see* Table 2S) for synthesis of these thioureas. In **Procedure D**, dioxan was used as solvent (10 mL for 1 mmol of each reagent, including 4 and 7) and the reaction was carried out under conventional heating method. The solvent-free microwave-assisted conditions were applied in Procedure E. In the refluxing cases (Proc. D), appropriate 2-aminopyrimidines **4a-l** and peracetylated glucopyranosyl isothiocyanate **7** were dissolved in anhydrous dioxane. Then, the reaction mixture was heated under refluxing for 14–16 h. Thioureas **8a-l** were obtained with yields of 54–76%. In MW irradiation cases (Proc. E), reaction mixture of appropriate 2-aminopyrimidines **4a-l** and peracetylated glucopyranosyl isothiocyanate **7** was grinded to mix together, and any solvent wasn't used. The solid reaction mixture obtained then was irradiated under microwave-assisted conditions. After first several minutes (usually, 2–3 min) of microwave irradiation (MWI), the reaction mixture became pasty and this reaction was complete for 3–10 min (Table 1). Thioureas were obtained yields of 67–82%. It showed that the essential

disadvantages of Procedure E were that the reaction time was prolonged (14 h) and the solvent was used in large amount (20 mL for 4 mmol of reactants). Meanwhile, the advantage of Procedure F was higher product yields with shorter reaction time, in addition, the green chemistry aspect of this reaction procedure that it carried out without any solvent (i.e., under solvent-free conditions).

Table 2 Synthesis of *N*-(per-*O*-acetyl- β -D-glucopyranosyl)-*N'*-(4,6-diarylpyrimidine-2-yl)thioureas (**8a-l**)

Compd.	R	Reaction times ^a		Yields (%) ^b		M.p. (°C)
		Procedure D (h)	Procedure E (min)	Procedure D	Procedure E	
8a	H	15	5	66	76	223–224
8b	4-F	14	5	76	79	201–202
8c	4-Cl	16	10	76	67	221–222
8d	3-Cl	14	5	76	76	132–133
8e	2-Cl	15	8	59	67	220–221
8f	4-Br	14	3	76	79	232–233
8g	4-Me	15	5	67	80	225–226
8h	4- ⁱ Pr	14	3	71	82	218–219
8i	4-OMe	14	3	72	72	195–196
8j	3-OMe	14	3	69	75	226–227
8k	2-OMe	15	3	54	73	253–254
8l	4-NMe ₂	15	9	69	80	199–200

^a **Procedure D:** Dioxan as solvent (10 mL for 1 mmol of each reagent) under conventional heating method; **Procedure E:** under solvent-free microwave-assisted conditions; ^b Isolated yields.

References

1. T. Narender and K. Papi Reddy, *Tetrahedron Letters*, 2007, **48**, 3177-3180.
2. K. Krohn, K. Steingröver and M. Srinivasa Rao, *Phytochemistry*, 2002, **61**, 931-936.
3. O. Nerya, R. Musa, S. Khatib, S. Tamir and J. Vaya, *Phytochemistry*, 2004, **65**, 1389-1395.
4. J.-H. Cheng, C.-F. Hung, S.-C. Yang, J.-P. Wang, S.-J. Won and C.-N. Lin, *Bioorganic & Medicinal Chemistry*, 2008, **16**, 7270-7276.
5. V. Balachandran, K. Anitha, B. Narayana, M. Karunanidhi and B. Revathi, *Materials Research Innovations*, 2019, **23**, 385-396.
6. Y. Zhao and Q. Song, *Organic Chemistry Frontiers*, 2016, **3**, 294-297.
7. G. Dutkiewicz, K. Veena, B. Narayana, H. S. Yathirajan and M. Kubicki, *Acta Crystallographica Section E*, 2010, **66**, o1243-o1244.
8. S.-L. Ng, I. A. Razak, H.-K. Fun, V. Shettigar, P. S. Patil and S. M. Dharmaprakash, *Acta Crystallographica Section E*, 2006, **62**, o2175-o2177.


9. H.-K. Fun, P. S. Patil, S. M. Dharmaprakash and S. Chantrapromma, *Acta Crystallographica Section E*, 2008, **64**, o1464.
10. S.-L. Ng, V. Shettigar, I. A. Razak, H.-K. Fun, P. S. Patil and S. M. Dharmaprakash, *Acta Crystallographica Section E*, 2006, **62**, o1421-o1423.
11. L. Wang, Y. Zhang, C.-R. Lu and D.-C. Zhang, *Acta Crystallographica Section C*, 2004, **60**, o696-o698.
12. V. Shettigar, M. M. Rosli, H.-K. Fun, I. A. Razak, P. S. Patil and S. M. Dharmaprakash, *Acta Crystallographica Section E*, 2006, **62**, o4128-o4129.
13. P. S. Patil, S. Chantrapromma, H.-K. Fun, S. M. Dharmaprakash and H. B. R. Babu, *Acta Crystallographica Section E*, 2007, **63**, o2612.
14. A. M. Asiri, M. Karabacak, S. Sakthivel, A. O. Al-youbi, S. Muthu, S. A. Hamed, S. Renuga and T. Alagesan, *Journal of Molecular Structure*, 2016, **1103**, 145-155.
15. N. D. Thanh and N. T. T. Mai, *Carbohydrate Research*, 2009, **344**, 2399-2405.

3. Molecular docking study


3. Induced fit docking study

3.1. For α -amylase on enzyme 4W93


H (**8a**), $G_{\text{score}} = -8.257$ kcal/mol, $IC_{50} = 64.32 \pm 1.15$ μ M




4-F (**8b**), $G_{\text{score}} = -9.176$ kcal/mol, $IC_{50} = 18.12 \pm 1.12$ μ M




4-Cl (**8c**), $G_{\text{score}} = -8.984$ kcal/mol, $IC_{50} = 25.22 \pm 1.12$ μM




3-Cl (**8d**), $G_{\text{score}} = -7.853$ kcal/mol, $IC_{50} = 74.51 \pm 1.13$ μM




2-Cl (**8e**), $G_{\text{score}} = -6.913$ kcal/mol, $IC_{50} = 93.12 \pm 1.12$ μM




4-Br (**8f**), $G_{\text{score}} = -9.542$ kcal/mol, $IC_{50} = 12.15 \pm 0.33$ μM




4-Me (**8g**), $G_{\text{score}} = -8.756$ kcal/mol, $IC_{50} = 35.12 \pm 1.15$ μM




4-*i*Pr (**8h**), $G_{\text{score}} = -8.995$ kcal/mol, $IC_{50} = 24.27 \pm 1.12$ μM




4-OMe (**8i**), $G_{\text{score}} = -8.916$ kcal/mol, $IC_{50} = 27.71 \pm 1.13$ μM



3-OMe (**8j**), $G_{\text{score}} = -8.437$ kcal/mol, $IC_{50} = 54.61 \pm 1.12$ μM



2-OMe (**8k**), $G_{\text{score}} = -9.815$ kcal/mol, $IC_{50} = 9.72 \pm 0.34$ μM



4-NMe₂ (**8l**), $G_{\text{score}} = -8.979$ kcal/mol, $IC_{50} = 25.74 \pm 1.12$ μM




Fig. 1S The mode of interaction in the 2D-presentation of ligand **8a-l** in the active pocket of enzyme 4W93 indicated the H bond, stacking π - π and lipophilic interactions of each ligand corresponding to the residues.






Fig. 2S Superimposing of ligands **8a-l** in active pocket of enzyme 4W93, where, compound **8a** (R=H, faded orange colour), **8b** (R=4-F, blue colour), **8c** (R=4-Cl, dark grey colour), **8d** (R=3-Cl, yellow colour), **8e** (R=2-Cl, faded yellow-green colour), **8f** (R=4-Br, green colour), **8g** (R=4-Me, grey colour), **8h** (R=4-*i*Pr, faded red-orange colour), **8i** (R=4-OMe, magenta colour), **8j** (R=3-OMe, faded azure colour), **8k** (R=2-OMe, violet colour), **8l** (R=4-NMe₂, cyan colour). Co-crystal, montbretin A, was in red colour.

3.2. For α -glucosidase on enzyme 3TOP


H (**8a**), $G_{\text{score}} = -9.456$ kcal/mol, $IC_{50} = 17.52 \pm 1.15$ μ M




4-F (**8b**), $G_{\text{score}} = -9.150$ kcal/mol, $IC_{50} = 27.45 \pm 1.12$ μ M




4-Cl (**8c**), $G_{\text{score}} = -6.929$ kcal/mol, $IC_{50} = 56.52 \pm 1.12$ μM




2-Cl (**8e**), $G_{\text{score}} = -9.911$ kcal/mol, $IC_{50} = 10.64 \pm 0.85$ μM




4-Me (**8g**), $G_{\text{score}} = -8.807$ kcal/mol, $IC_{50} = 36.52 \pm 1.12$ μM




3-Cl (**8d**), $G_{\text{score}} = -9.730$ kcal/mol, $IC_{50} = 14.45 \pm 0.84$ μM




4-Br (**8f**), $G_{\text{score}} = -9.275$ kcal/mol, $IC_{50} = 23.62 \pm 1.15$ μM




4-*i*Pr (**8h**), $G_{\text{score}} = -8.482$ kcal/mol, $IC_{50} = 47.51 \pm 1.12$ μM




4-OMe (**8i**), $G_{\text{score}} = -9.929$ kcal/mol, $IC_{50} = 9.73 \pm 0.72$ μM



2-OMe (**8k**), $G_{\text{score}} = -8.667$ kcal/mol, $IC_{50} = 43.63 \pm 1.15$ μM



3-OMe (**8j**), $G_{\text{score}} = -10.175$ kcal/mol, $IC_{50} = 8.35 \pm 0.88$ μM



4-NMe₂ (**8l**), $G_{\text{score}} = -9.334$ kcal/mol, $IC_{50} = 21.16 \pm 1.12$ μM




Fig. 3S The mode of interaction in the 2D-presentation of ligand **8a-l** in the active pocket of enzyme 3TOP 4W93 indicated the H bond, stacking π - π and lipophilic interactions of each ligand corresponding to the residues..






Fig. 4S Superimposing of ligands **8a-l** in active pocket of enzyme 3TOP, where, compound **8a** (R=H, faded orange colour), **8b** (R=4-F, blue colour), **8c** (R=4-Cl, dark grey colour), **8d** (R=3-Cl, yellow colour), **8e** (R=2-Cl, faded yellow-green colour), **8f** (R=4-Br, green colour), **8g** (R=4-Me, grey colour), **8h** (R=4-*i*Pr, faded red-orange colour), **8i** (R=4-OMe, magenta colour), **8j** (R=3-OMe, faded azure colour), **8k** (R=2-OMe, violet colour), **8l** (R=4-NMe₂, cyan colour). Co-crystal, acarbose was in red colour.

3.3. For dipeptidyl peptidase-4 on enzyme 3W2T


H (**8a**), $G_{\text{score}} = -7.983$ kcal/mol, $IC_{50} = 5.52 \pm 0.13$ μ M




4-F (**8b**), $G_{\text{score}} = -6.042$ kcal/mol, $IC_{50} = 45.23 \pm 2.32$ μ M




4-Cl (**8c**), $G_{\text{score}} = -6.940$ kcal/mol, $IC_{50} = 12.78 \pm 0.23$ μM




3-Cl (**8d**), $G_{\text{score}} = -6.895$ kcal/mol, $IC_{50} = 17.31 \pm 0.32$ μM




2-Cl (**8e**), $G_{\text{score}} = -6.594$ kcal/mol, $IC_{50} = 41.57 \pm 2.21$ μM




4-Br (**8f**), $G_{\text{score}} = -10.512$ kcal/mol, $IC_{50} = 2.23 \pm 0.03$ μM




4-Me (**8g**), $G_{\text{score}} = -9.660$ kcal/mol, $IC_{50} = 4.62 \pm 0.14$ μM




4-ⁱPr (**8h**), $G_{\text{score}} = -7.031$ kcal/mol, $IC_{50} = 8.19 \pm 0.14$ μM




4-OMe (**8i**), $G_{\text{score}} = -6.611$ kcal/mol, $IC_{50} = 35.71 \pm 0.23$ μM



3-OMe (**8j**), $G_{\text{score}} = -6.704$ kcal/mol, $IC_{50} = 25.71 \pm 0.32$ μM



2-OMe (**8k**), $G_{\text{score}} = -6.727$ kcal/mol, $IC_{50} = 24.32 \pm 0.51$ μM



4-NMe₂ (**8l**), $G_{\text{score}} = -5.173$ kcal/mol, $IC_{50} = 64.27 \pm 2.11$ μM




Fig. 5S. The mode of interaction in the 2D-presentation of ligand **8a-l** in the active pocket of enzyme 3W2T 4W93 indicated the H bond, stacking π - π and lipophilic interactions of each ligand corresponding to the residues.






Fig. 6S Superimposing of ligands **8a-l** in active pocket of enzyme 3W2T, where, compound **8a** (R=H, faded orange colour), **8b** (R=4-F, blue colour), **8c** (R=4-Cl, dark grey colour), **8d** (R=3-Cl, yellow colour), **8e** (R=2-Cl, faded yellow-green colour), **8f** (R=4-Br, green colour), **8g** (R=4-Me, grey colour), **8h** (R=4-*i*Pr, faded red-orange colour), **8i** (R=4-OMe, magenta colour), **8j** (R=3-OMe, faded azure colour), **8k** (R=2-OMe, violet colour), **8l** (R=4-NMe₂, cyan colour). Co-crystal, vildagliptin was in red colour.


3.4. For protein tyrosine phosphatase 1B on enzyme INNY

H (**8a**), $G_{\text{score}} = -8.468$ kcal/mol, $IC_{50} = 8.72 \pm 0.23$ μM


4-F (**8b**), $G_{\text{score}} = -8.594$ kcal/mol, $IC_{50} = 7.12 \pm 0.14$ μM




4-Cl (**8c**), $G_{\text{score}} = -6.483$ kcal/mol, $\text{IC}_{50} = 38.43 \pm 1.13$ μM




3-Cl (**8d**), $G_{\text{score}} = -8.755$ kcal/mol, $\text{IC}_{50} = 5.31 \pm 0.14$ μM




2-Cl (**8e**), $G_{\text{score}} = -6.971$ kcal/mol, $\text{IC}_{50} = 25.24 \pm 0.37$ μM




4-Br (**8f**), $G_{\text{score}} = -8.724$ kcal/mol, $\text{IC}_{50} = 5.62 \pm 0.13$ μM




4-Me (**8g**), $G_{\text{score}} = -5.924$ kcal/mol, $\text{IC}_{50} = 58.32 \pm 1.16$ μM




4-ⁱPr (**8h**), $G_{\text{score}} = -9.184$ kcal/mol, $\text{IC}_{50} = 2.74 \pm 0.03$ μM




4-OMe (**8i**), $G_{\text{score}} = -8.327$ kcal/mol, $IC_{50} = 10.31 \pm 0.36$ μM



3-OMe (**8j**), $G_{\text{score}} = -8.272$ kcal/mol, $IC_{50} = 12.17 \pm 0.54$ μM



2-OMe (**8k**), $G_{\text{score}} = -6.592$ kcal/mol, $IC_{50} = 31.22 \pm 1.41$ μM



4-NMe₂ (**8l**), $G_{\text{score}} = -8.153$ kcal/mol, $IC_{50} = 14.13 \pm 0.22$ μM




Fig. 7S. The mode of interaction in the 2D-presentation of ligand **8a-l** in the active pocket of enzyme 1NNY 4W93 indicated the H bond, stacking π - π and lipophilic interactions of each ligand corresponding to the residues.






Fig. 8S Superimposing of ligands **8a-l** in active pocket of enzyme 1NNY, where, compound **8a** (R=H, faded orange colour), **8b** (R=4-F, blue colour), **8c** (R=4-Cl, dark grey colour), **8d** (R=3-Cl, yellow colour), **8e** (R=2-Cl, faded yellow-green colour), **8f** (R=4-Br, green colour), **8g** (R=4-Me, grey colour), **8h** (R=4-*i*Pr, faded red-orange colour), **8i** (R=4-OMe, magenta colour), **8j** (R=3-OMe, faded azure colour), **8k** (R=2-OMe, violet colour), **8l** (R=4-NMe₂, cyan colour). Co-crystal, ursolic acid was in red colour.


4. NMR & MS Spectra


4.1. 1-(2,3,4,6-Tetra-O-acetyl- β -D-glucopyranosyl)-3-[4-(phenyl)-6-(4-bromophenyl)pyrimidin-2-yl]thiourea (**8a**)






4.2. 1-(2,3,4,6-Tetra-O-acetyl- β -D-glucopyranosyl)-3-[4-(4-bromophenyl)-6-(4-fluorophenyl)pyrimidin-2-yl]thiourea (8b)





4.3. 1-(2,3,4,6-Tetra-O-acetyl- β -D-glucopyranosyl)-3-[4-(4-bromophenyl)-6-(4-fluorophenyl)pyrimidin-2-yl]thiourea (8b)




Mau Chi Mai_Nguyen do_19/7/2006



Mai_Thioure p-Br 100 (2.350)

Chi xuất hiện các pic tu 1% trở lên

Magnet EI+
8.35e4





4.3. 1-(2,3,4,6-Tetra-O-acetyl- β -D-glucopyranosyl)-3-[4-(4-bromophenyl)-6-(4-chlorophenyl)pyrimidin-2-yl]thiourea (8c)





H NMR



4.4. 1-(2,3,4,6-Tetra-O-acetyl- β -D-glucopyranosyl)-3-[4-(4-bromophenyl)-6-(3-chlorophenyl)pyrimidin-2-yl]thiourea (8d)





4.5. 1-(2,3,4,6-Tetra-O-acetyl- β -D-glucopyranosyl)-3-[4-(4-bromophenyl)-6-(2-chlorophenyl)pyrimidin-2-yl]thiourea (8e)





4.6. 1-(2,3,4,6-Tetra-O-acetyl- β -D-glucopyranosyl)-3-[4,6-bis(4-bromo-phenyl)pyrimidin-2-yl]thiourea (8f)





4.7. 1-(2,3,4,6-Tetra-O-acetyl- β -D-glucopyranosyl)-3-[4-(4-bromophenyl)-6-(4-methylphenyl)pyrimidin-2-yl]thiourea (8g)




4.8. 1-(2,3,4,6-Tetra-O-acetyl- β -D-glucopyranosyl)-3-[4-(4-bromophenyl)-6-(4-isopropylphenyl)pyrimidin-2-yl]thiourea (8h)





4.9. 1-(2,3,4,6-Tetra-O-acetyl- β -D-glucopyranosyl)-3-[4-(4-bromophenyl)-6-(4-methoxyphenyl)pyrimidin-2-yl]thiourea (8i)




4.10. 1-(2,3,4,6-Tetra-O-acetyl- β -D-glucopyranosyl)-3-[4-(4-bromophenyl)-6-(3-methoxyphenyl)pyrimidin-2-yl]thiourea (8j)



4.11. 1-(2,3,4,6-Tetra-O-acetyl- β -D-glucopyranosyl)-3-[4-(4-bromophenyl)-6-(2-methoxyphenyl)pyrimidin-2-yl]thiourea (8k)



4.12. 1-(2,3,4,6-Tetra-O-acetyl- β -D-glucopyranosyl)-3-[4-(4-bromophenyl)-6-(4-dimethylaminophenyl)pyrimidin-2-yl]thiourea (8l)



T.P. met₂ - P. Ba

